BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19855091)

  • 1. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
    Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
    Gibbs A; Schwartzman J; Deng V; Alumkal J
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16663-8. PubMed ID: 19805354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
    Saporita AJ; Ai J; Wang Z
    Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
    Jadhavar PS; Ramachandran SA; Riquelme E; Gupta A; Quinn KP; Shivakumar D; Ray S; Zende D; Nayak AK; Miglani SK; Sathe BD; Raja M; Farias O; Alfaro I; Belmar S; Guerrero J; Bernales S; Chakravarty S; Hung DT; Lindquist JN; Rai R
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5222-5228. PubMed ID: 27717544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
    Basak S; Pookot D; Noonan EJ; Dahiya R
    Mol Cancer Ther; 2008 Oct; 7(10):3195-202. PubMed ID: 18852123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
    Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
    Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling.
    Kekatpure VD; Dannenberg AJ; Subbaramaiah K
    J Biol Chem; 2009 Mar; 284(12):7436-45. PubMed ID: 19158084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
    Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
    Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
    Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
    Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.
    Dar JA; Masoodi KZ; Eisermann K; Isharwal S; Ai J; Pascal LE; Nelson JB; Wang Z
    J Steroid Biochem Mol Biol; 2014 Sep; 143():473-80. PubMed ID: 24662325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone.
    Murphy PJ; Morishima Y; Kovacs JJ; Yao TP; Pratt WB
    J Biol Chem; 2005 Oct; 280(40):33792-9. PubMed ID: 16087666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
    O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
    Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
    Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
    Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
    Trtková K; Pašková L; Matiješčuková N; Kolář Z
    Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.